Literature DB >> 9310209

Update: trends in AIDS incidence -- United States, 1996.

.   

Abstract

Provisional surveillance data about acquired immunodeficiency syndrome (AIDS) for the first 6 months of 1996 indicated a decrease in deaths among persons with AIDS, attributed primarily to the effect of antiretroviral therapies on the survival of persons infected with human immunodeficiency virus (HIV). This report describes a decline in AIDS incidence during 1996 compared with 1995 and the continued decline in AIDS deaths; the findings indicate that HIV therapies are having a widespread beneficial impact on the rate of HIV disease progression in the United States.

Entities:  

Mesh:

Year:  1997        PMID: 9310209

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  15 in total

1.  When should we delay highly active antiretroviral therapy?

Authors:  D R Bangsberg; A Moss
Journal:  J Gen Intern Med       Date:  1999-07       Impact factor: 5.128

2.  Multicenter evaluation of methods to quantitate human immunodeficiency virus type 1 RNA in seminal plasma.

Authors:  S A Fiscus; D Brambilla; R W Coombs; B Yen-Lieberman; J Bremer; A Kovacs; S Rasheed; M Vahey; T Schutzbank; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  The Changing Epidemic of HIV.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

4.  End-of-life care in HIV disease: let's talk.

Authors:  I B Wilson
Journal:  J Gen Intern Med       Date:  1997-12       Impact factor: 5.128

5.  Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy.

Authors:  P Tebas; W G Powderly; S Claxton; D Marin; W Tantisiriwat; S L Teitelbaum; K E Yarasheski
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

6.  Two approaches to measuring quality of life in the HIV/AIDS population: HAT-QoL and MOS-HIV.

Authors:  W C Holmes; J A Shea
Journal:  Qual Life Res       Date:  1999-09       Impact factor: 4.147

7.  Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.

Authors:  B M Sadler; C D Hanson; G E Chittick; W T Symonds; N S Roskell
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

8.  Sexual diversity among black men who have sex with men in an inner-city community.

Authors:  Maureen Miller; Malin Serner; Meghan Wagner
Journal:  J Urban Health       Date:  2005-02-28       Impact factor: 3.671

9.  HIV-seropositive individuals' optimistic beliefs about prognosis and relation to medication and safe sex adherence.

Authors:  William C Holmes; Joseph L Pace
Journal:  J Gen Intern Med       Date:  2002-09       Impact factor: 5.128

10.  Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users.

Authors:  Frederick L Altice; Sandra Springer; Marta Buitrago; David P Hunt; Gerald H Friedland
Journal:  J Urban Health       Date:  2003-09       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.